Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

Type1 Diabetes Mellitus Clinical Trial

— TN-23  

Official title:

Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03396484
• Other study ID #: Methyldopa
• Secondary ID: UC4DK106993UC4DK
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 2020
• Est. completion date: March 2022

Study information

• Verified date: June 2020
• Source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study is to see if methyldopa can change the immune system's attack on insulin producing cells in people at early stages of type 1 diabetes.

Description:

The study is a randomized, double blinded, placebo-controlled, multi-center crossover clinical trial.

Eligible subjects will be randomized in a 1:1 allocation ratio to one of two treatment schedules: first methyldopa then placebo vs. first placebo then methyldopa.

The study objective is to assess the safety, efficacy, and mode of action of methyldopa to reduce DQ8 antigen presentation in individuals at Stage 1 and 2 of type 1 diabetes (T1D).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years and older

Eligibility

Inclusion Criteria:

• Participant in TrialNet Pathway to Prevention Study (TN01)

• Willing to provide Informed Consent or, if the subject is <18 years of age, have a parent or legal guardian provide Informed Consent

• Confirmed positive for one or more autoantibodies, one of which is insulin autoantibody (mIAA)

• Positive for at least one gene encoding HLA-DQ8 (DQB*0302)

• If a female participant with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing prior to randomization and during the study

• Have normal or abnormal glucose tolerance on OGTT performed within 7 weeks of randomization

Exclusion Criteria:

• Inability or unwillingness of a participant to give written informed consent or comply with study protocol

• History of clinically significant anemia or Hemoglobin <10 g/dl

• Evidence of liver dysfunction

• History of renal insufficiency

• History of symptomatic hypotension including positional hypotension

• Systolic BP < 100 mmHg for adults or blood pressure < 5th percentile for age/height/gender in children and adolescents

• Use of a treatment that is known to cause a significant, ongoing change in the course of diabetes or immunologic status, within 4 weeks prior to participation. This includes high-dose inhaled, extensive topical or systemic glucocorticoids

• Females who are pregnant at the time of screening, breastfeeding or unwilling to defer pregnancy during the 16-month study period. (Female participant must be at least 100 days postpartum before enrollment into study)

• Unable to avoid concurrent antihypertensive medications, monoamine oxidase (MAO) inhibitors, lithium, or medications containing ferrous sulfate or ferrous gluconate

• Unable to avoid medications that affect stomach pH, such as proton pump inhibitors or histamine H2 receptor blockers

• Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type1 Diabetes Mellitus

Intervention

Drug:
• Methyldopa
Tablet for oral dosing
• Placebo
Tablet for oral dosing

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DQ8 Antigen Presentation	insulin peptide-specific DQ8 antigen presentation	6 months after initiation of treatment

External Links

•   TrialNet Public Website